Identifying biomarkers of response to modified FOLFIRINOX regimens using patient derived xenograft mouse models of pancreatic ductal adenocarcinoma Public Deposited
- Last Modified
- March 19, 2019
- Creator
-
Eldridge, Meagan
- Affiliation: School of Medicine, Department of Pharmacology
- Abstract
- Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with limited effective therapies. FOLFIRINOX is a chemotherapeutic regimen for patients with metastatic disease that provides an unprecedented median overall survival of 11.1 months. However, significant toxicities necessitate dose reductions and limit the number of patients eligible for FOLFIRINOX treatment. I used patient derived xenograft (PDX) mouse models of PDAC to assess efficacy of modified regimens and determine if intra-tumoral heterogeneity plays a role in response. I also used RNA sequencing of PDX tumors to identify potential biomarkers of response. No significant differences in response to standard and modified FOLFIRINOX regimens were observed; however, intra-tumoral heterogeneity affected responses of one PDX tumor line to modified regimens. Biomarkers associated with differential responses could not be identified by RNA sequencing. RNA sequencing data confirmed previously identified PDAC subtypes, classical and basal-like.
- Date of publication
- December 2014
- Keyword
- Subject
- DOI
- Identifier
- Resource type
- Rights statement
- In Copyright
- Advisor
- Graves, Lee
- Nicholas, Robert
- Yeh, Jen Jen
- Degree
- Master of Science
- Degree granting institution
- University of North Carolina at Chapel Hill Graduate School
- Graduation year
- 2014
- Language
- Publisher
- Place of publication
- Chapel Hill, NC
- Access
- There are no restrictions to this item.
- Parents:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
|
Eldridge_unc_0153M_15053.pdf | 2019-04-10 | Public |
|